FindTrial
Sign In

Medication Therapy Management and Pharmacogenetics on Oral Anticoagulants

Medication Therapy Management on Anticoagulants and Incorporation of Pharmacogenetics-Guided Individualized Dosing of Warfarin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030250
Enrollment
150
Registered
2021-01-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D683- Hemorrhagic disorder due to circulating anticoagulants

Interventions

None listed

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients prescribed with anticoagulants in surgery, cardio-thoracic and cardiology units (Both in-patients and out-patients)

Exclusion criteria

Exclusion criteria: Critically ill patients Patients with psychiatric problems Pregnant women Patients not willing to participate in the study For PGx study: Other anticoagulants, inhibitors and inducers of warfarin excluded

Design outcomes

Primary

MeasureTime frame
Impact of MTM services Knowledge and Adherence Pharmacogenetics of Warfarin INR monitoring Timepoint: 0, 4, 8 months—

Secondary

MeasureTime frame
Direct costs incurred Timepoint: 0, 4, 8 months—

Countries

India

Contacts

Public ContactDr Mahadev Rao

Manipal College of Pharmaceutical Sciences

rajesh.v@manipal.edu9538417313

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026